Optimal Norethisterone Dosing for Adenomyosis
For adenomyosis treatment, norethisterone acetate should be administered continuously from day 5 to day 21 of the menstrual cycle, as this regimen demonstrates superior efficacy in controlling abnormal uterine bleeding compared to intermittent dosing.
Dosing Regimen
The evidence supports continuous administration over intermittent protocols:
- Continuous regimen: Day 5 to day 21 of the menstrual cycle 1
- Intermittent regimen: Day 16 for 10 days (less effective) 1
The continuous approach showed highly significant reduction in menorrhagia (P < 0.001) with an area under the curve of 0.973 for predicting decreased menstrual bleeding and pain 1. This represents robust predictive value for symptom improvement.
Clinical Efficacy Data
Low-dose norethisterone acetate (specific dosing not detailed in the primary studies, but FDA labeling indicates 0.35 mg for contraceptive use 2) has demonstrated:
- Significant improvement in both dysmenorrhea and bleeding 3
- Effective, well-tolerated, and inexpensive alternative to surgery 3
- No correlation between age and treatment response 3
Long-Term Management Considerations
When norethisterone is used as second-line therapy (after dienogest, levonorgestrel-IUD, or other progestins), it serves as an effective option for patients with:
Combination Therapy Option
For refractory cases with coexisting fibroids, consider relugolix 40 mg + estradiol 1 mg + norethisterone acetate 0.5 mg as a fixed-dose combination:
- Complete resolution of dysmenorrhea and pelvic pain (VAS = 0) 5
- Cessation of menstrual bleeding (PBAC = 0) 5
- Uterine volume reduction of 8.6-58.3% 5
- Well-tolerated with no discontinuations in case series 5
Critical Pitfalls to Avoid
Intermittent dosing (day 16 for 10 days) should be avoided as it shows inferior efficacy compared to continuous administration 1. The continuous regimen from day 5 to day 21 provides better menstrual control and pain relief.
Safety Profile
Norethisterone at contraceptive doses (0.35 mg) shows reassuring thrombotic risk profile with no excess venous thromboembolism risk 6. However, monitor for:
- Menstrual irregularities (most common side effect) 2
- Headache requiring discontinuation if severe/focal 2
- Decreased milk production in nursing mothers (rare) 2
The continuous day 5-21 regimen represents the evidence-based approach for maximizing symptom control while maintaining tolerability in adenomyosis management.